FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000958077> ?p ?o ?g. }

• W2000958077 endingPage "165" @default.
• W2000958077 startingPage "165" @default.
• W2000958077 abstract "Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control Harold E Bays,1 Eliot A Brinton,2 Joseph Triscari,3 Erluo Chen,3 Darbie Maccubbin,3 Alexandra A MacLean,3 Kendra L Gibson,3 Rae Ann Ruck,3 Amy O Johnson-Levonas,3 Edward A O’Neill,3 Yale B Mitchel3 1Louisville Metabolic & Atherosclerosis Research Center (L-MARC), Louisville, KY, USA; 2Utah Foundation for Biomedical Research, Salt Lake City, UT, USA; 3Merck & Co, Inc., Whitehouse Station, NJ, USA Background: The degree of glycemic control in patients with type 2 diabetes mellitus (T2DM) may alter lipid levels and may alter the efficacy of lipid-modifying agents. Objective: Evaluate the lipid-modifying efficacy of extended-release niacin/laropiprant (ERN/LRPT) in subgroups of patients with T2DM with better or poorer glycemic control. Methods: Post hoc analysis of clinical trial data from patients with T2DM who were randomized 4:3 to double-blind ERN/LRPT or placebo (n=796), examining the lipid-modifying effects of ERN/LRPT in patients with glycosylated hemoglobin or fasting plasma glucose levels above and below median baseline levels. Results: At Week 12 of treatment, ERN/LRPT significantly improved low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol, triglycerides, and lipoprotein (a), compared with placebo, with equal efficacy in patients above or below median baseline glycemic control. Compared with placebo, over 36 weeks of treatment more patients treated with ERN/LRPT had worsening of their diabetes and required intensification of antihyperglycemic medication, irrespective of baseline glycemic control. Incidences of other adverse experiences were generally low in all treatment groups. Conclusion: The lipid-modifying effects of ERN/LRPT are independent of the degree of baseline glycemic control in patients with T2DM (NCT00485758). Keywords: lipid-modifying agents, hyperglycemia, LDL, HDL, triglycerides" @default.
• W2000958077 created "2016-06-24" @default.
• W2000958077 creator A5020230532 @default.
• W2000958077 creator A5021709407 @default.
• W2000958077 creator A5032509000 @default.
• W2000958077 creator A5041403685 @default.
• W2000958077 creator A5047080636 @default.
• W2000958077 creator A5047369181 @default.
• W2000958077 creator A5049530400 @default.
• W2000958077 creator A5053191013 @default.
• W2000958077 creator A5067906247 @default.
• W2000958077 creator A5072302674 @default.
• W2000958077 creator A5077958792 @default.
• W2000958077 date "2015-02-01" @default.
• W2000958077 modified "2023-09-23" @default.
• W2000958077 title "Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control" @default.
• W2000958077 cites W1481564277 @default.
• W2000958077 cites W1505444180 @default.
• W2000958077 cites W1856460279 @default.
• W2000958077 cites W1965505708 @default.
• W2000958077 cites W2019863077 @default.
• W2000958077 cites W2035440468 @default.
• W2000958077 cites W2048244406 @default.
• W2000958077 cites W2057651652 @default.
• W2000958077 cites W2068615855 @default.
• W2000958077 cites W2070855777 @default.
• W2000958077 cites W2074571762 @default.
• W2000958077 cites W2079875634 @default.
• W2000958077 cites W2109712320 @default.
• W2000958077 cites W2124892367 @default.
• W2000958077 cites W2124931981 @default.
• W2000958077 cites W2141036185 @default.
• W2000958077 cites W2147674804 @default.
• W2000958077 cites W2165605025 @default.
• W2000958077 cites W2189339462 @default.
• W2000958077 cites W2324712847 @default.
• W2000958077 cites W2410405995 @default.
• W2000958077 cites W2411329118 @default.
• W2000958077 cites W4230870013 @default.
• W2000958077 cites W68098806 @default.
• W2000958077 doi "https://doi.org/10.2147/vhrm.s70907" @default.
• W2000958077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4348131" @default.
• W2000958077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25750540" @default.
• W2000958077 hasPublicationYear "2015" @default.
• W2000958077 type Work @default.
• W2000958077 sameAs 2000958077 @default.
• W2000958077 citedByCount "4" @default.
• W2000958077 countsByYear W20009580772016 @default.
• W2000958077 countsByYear W20009580772017 @default.
• W2000958077 countsByYear W20009580772021 @default.
• W2000958077 countsByYear W20009580772023 @default.
• W2000958077 crossrefType "journal-article" @default.
• W2000958077 hasAuthorship W2000958077A5020230532 @default.
• W2000958077 hasAuthorship W2000958077A5021709407 @default.
• W2000958077 hasAuthorship W2000958077A5032509000 @default.
• W2000958077 hasAuthorship W2000958077A5041403685 @default.
• W2000958077 hasAuthorship W2000958077A5047080636 @default.
• W2000958077 hasAuthorship W2000958077A5047369181 @default.
• W2000958077 hasAuthorship W2000958077A5049530400 @default.
• W2000958077 hasAuthorship W2000958077A5053191013 @default.
• W2000958077 hasAuthorship W2000958077A5067906247 @default.
• W2000958077 hasAuthorship W2000958077A5072302674 @default.
• W2000958077 hasAuthorship W2000958077A5077958792 @default.
• W2000958077 hasBestOaLocation W20009580771 @default.
• W2000958077 hasConcept C126322002 @default.
• W2000958077 hasConcept C134018914 @default.
• W2000958077 hasConcept C142724271 @default.
• W2000958077 hasConcept C204787440 @default.
• W2000958077 hasConcept C27081682 @default.
• W2000958077 hasConcept C2777180221 @default.
• W2000958077 hasConcept C2778096610 @default.
• W2000958077 hasConcept C2778163477 @default.
• W2000958077 hasConcept C2778270857 @default.
• W2000958077 hasConcept C2780072125 @default.
• W2000958077 hasConcept C2780092750 @default.
• W2000958077 hasConcept C2780473172 @default.
• W2000958077 hasConcept C2910068830 @default.
• W2000958077 hasConcept C555293320 @default.
• W2000958077 hasConcept C71924100 @default.
• W2000958077 hasConcept C90924648 @default.
• W2000958077 hasConceptScore W2000958077C126322002 @default.
• W2000958077 hasConceptScore W2000958077C134018914 @default.
• W2000958077 hasConceptScore W2000958077C142724271 @default.
• W2000958077 hasConceptScore W2000958077C204787440 @default.
• W2000958077 hasConceptScore W2000958077C27081682 @default.
• W2000958077 hasConceptScore W2000958077C2777180221 @default.
• W2000958077 hasConceptScore W2000958077C2778096610 @default.
• W2000958077 hasConceptScore W2000958077C2778163477 @default.
• W2000958077 hasConceptScore W2000958077C2778270857 @default.
• W2000958077 hasConceptScore W2000958077C2780072125 @default.
• W2000958077 hasConceptScore W2000958077C2780092750 @default.
• W2000958077 hasConceptScore W2000958077C2780473172 @default.
• W2000958077 hasConceptScore W2000958077C2910068830 @default.
• W2000958077 hasConceptScore W2000958077C555293320 @default.
• W2000958077 hasConceptScore W2000958077C71924100 @default.
• W2000958077 hasConceptScore W2000958077C90924648 @default.
• W2000958077 hasLocation W20009580771 @default.
• W2000958077 hasLocation W20009580772 @default.

• next